Searched over 200M research papers for "cancer pustules"
10 papers analyzed
Some studies suggest that cancer treatments like Erlotinib and Atezolizumab can cause pustular skin conditions, while other studies indicate that these conditions can also be related to infections, autoimmune reactions, or drug side effects.
20 papers analyzed
Cancer-related pustules are a rare but significant dermatological manifestation in patients undergoing cancer treatment. These pustules can arise due to various factors, including drug reactions, infections, and immune responses. Understanding the etiology and management of these pustules is crucial for improving patient outcomes.
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been associated with acute generalized exanthematous pustulosis (AGEP) in lung cancer patients. AGEP is characterized by erythema and multiple pustules, often accompanied by fever and fatigue. Histological examination typically reveals intraepidermal pustules with neutrophil and eosinophil infiltration. Discontinuation of erlotinib and administration of systemic corticosteroids usually resolve the condition .
Atezolizumab, an immune checkpoint inhibitor targeting PD-L1, can induce palmoplantar pustulosis (PPP). This condition manifests as vesicles, pustules, and scaly erythema on the palms and soles. Histological findings include neutrophil accumulation and microabscess formation. Discontinuation of atezolizumab often leads to improvement in symptoms, suggesting a direct link between the drug and PPP.
Gefitinib, another EGFR inhibitor, has been linked to erosive pustular dermatosis of the scalp. This condition presents with erythematous erosive alopecia and pustules. Treatment typically involves discontinuation of gefitinib, which leads to rapid improvement of the lesions .
In immunosuppressed cancer patients, tinea corporis can present with widespread erosions and annular pustules, mimicking more serious dermatoses. Skin biopsy and cultures are essential for accurate diagnosis. Treatment with antifungal agents like griseofulvin can effectively clear the lesions.
MRSA infections can complicate the clinical picture in cancer patients, particularly those on EGFR inhibitors. These infections often present with pustules and require targeted antibiotic therapy for resolution.
Solid pseudopapillary tumors (SPT) of the pancreas can produce G-CSF, leading to neutrophilic dermatoses characterized by scattered pustules and plaques. Surgical resection of the tumor typically results in the resolution of skin symptoms, highlighting the importance of considering tumor-related factors in the differential diagnosis.
Subcorneal pustular dermatosis, although rare, can occur in cancer patients and is characterized by symmetrical eruptions with erythema and flaccid pustules. Treatment-resistant cases may benefit from novel therapies like infliximab, an anti-tumor necrosis factor alpha antibody.
Cancer-related pustules are a diverse group of dermatological conditions that can arise due to drug reactions, infections, or tumor-related factors. Accurate diagnosis and appropriate management are essential for improving patient outcomes. Clinicians should be aware of these potential complications and consider them in the differential diagnosis when treating cancer patients with pustular eruptions.
Most relevant research papers on this topic